12931_2018_751_MOESM1_ESM.jpg (48.04 kB)
Additional file 1: of A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial
figure
posted on 2018-04-04, 05:00 authored by Timm Greulich, Jens Hohlfeld, Petra Neuser, Katrin Lueer, Andreas Klemmer, Carmen Schade-Brittinger, Susanne Harnisch, Holger Garn, Harald Renz, Ursula Homburg, Jonas Renz, Anne Kirsten, Frauke Pedersen, Meike MĂźller, Claus Vogelmeier, Henrik WatzFigure S1. Study Design: After the informed consent and screening visits patients were randomized in a 1:1 ratio and treated with SB010 mg bid or matching placebo via AKITA inhalation for 28 days. A follow-up visit was conducted 4 weeks after termination of IMP treatment. (JPEG 48Â kb)
